Literature DB >> 11089514

The use of rizatriptan in the treatment of acute, multiple migraine attacks.

J R Saper1.   

Abstract

Therapy for migraine can be classified as preventive or acute. Preventive therapy is intended to reduce the frequency of headache, whereas the goal of acute migraine therapy is to optimize the patient's ability to function by reversing, aborting, or reducing pain and migraine-associated symptoms. Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine. Clinical studies of this drug have demonstrated its efficacy, safety, and tolerability when used as therapy for acute attacks on multiple occasions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089514

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

Authors:  T Iwasa; H Sano; A Sugiura; N Uchiyama; K Hara; H Okochi; K Nakagawa; T Yasumori; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 3.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.